PremiumCompany AnnouncementsHoth Therapeutics Faces Nasdaq Compliance Challenge Hoth Therapeutics reports preclinical data for HT-KIT Hoth Therapeutics granted Japanese patent for novel RNA-based cancer therapy PremiumThe FlyHoth Therapeutics reports data from its Alzheimer’s candidate HT-ALZ Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application Hoth Therapeutics announces new patent claim and begins GLP-compliant study PremiumThe FlyHoth Therapeutics announces collaboration with OnTargetx R&D Hoth Therapeutics regains compliance with Nasdaq listing rules Hoth Therapeutics expands IP portfolio with patent application acquisitions 
